ShareThis Page
John Dorfman

Top winners and losers You May Never Have Heard Of

John Dorfman
| Monday, Dec. 18, 2017, 11:00 p.m.

Have you ever heard of Saudi American Holdings? Madrigal Pharmaceuticals?

No? I thought not.

This weekend, I searched the universe of about 3,300 U.S. stocks with a market value of $500 million or more, looking for the five biggest gainers year-to-date, and the five largest losers. Some of the names may surprise you.

Saudi American

Who or what is Saudi American Holdings Corp. (SAHN)? That's a mystery. Based in Fort Lauderdale, Fla., it has a market value of just more than $1 billion, and is up 650 percent this year.

According to most financial databases, the company does shipping in Saudi Arabia and aircraft maintenance and repairs in the United States. But one database says it develops software for the dental industry.

When I attempted last weekend to find the company's filings on the Security and Exchange Commission website, there were none after 2007. Avoid.


Madrigal Pharmaceuticals Inc. (MDGL) is a biotech company in Fort Washington, Pa., working on drugs for hepatitis and cardiovascular diseases. The stock has climbed this year from $14.90 to $82.47 a share, on good (but still preliminary) clinical trial results. Avoid.

Sangamo Therapeutics

Sangamo Therapeutics Inc. (SGMO), which hails from Richmond, Calif., is a biotech firm expected to generate a little over $35 million in revenue this year and a little over $56 million in 2018. It is still losing money, however, and the stock sells for 38 times revenue, so I'm unenthusiastic. Avoid.

Straight Path

Straight Path Communications Inc. (STRP) jumped in April and May as a bidding war broke out between Verizon and AT&T to buy the company. Verizon won. But all the action is over now.


Based in Berkeley, Calif., Dynavax Technologies Corp. is working on medications to stimulate the body's immune system. It has partnerships with major drug companies but is expected to glean only $16 million in revenue this year. The stock sells for 98 times revenue, and there are no earnings yet. Avoid.

Last Frontier?

The most battered stock — down 84 percent year to date — is Frontier Communications Corp. (FTR), which provides phone, internet and TV service to about 5.4 million customers in about 30 states. Of 17 analysts who cover it, only two rate it a buy. That arouses my contrarian instincts, but then I looked at the company's long-term debt — $17 billion and growing. Avoid.

Wrong Aid

Competing with CVS and Walgreens is no picnic. On top of that, drugstores are losing business to internet vendors, and may lose more. Rite Aid Corp. (RAD) is suffering its second consecutive year of diminishing profits, and analysts expect it to fall into the red soon. Avoid.


Down 69 percent is Coherus Biosciences Inc. (CHRS), a biotech company in Redwood City, Calif., that attempts to develop biosimilars for existing medicines. At today's reduced price of about $9, Coherus wins buy ratings from eight of nine analysts. I don't usually side with the majority, but this time I do. Buy.

Friendly Nabors

A land driller based in Houston, Nabors Industries Ltd. is down 67 percent this year, but its fortunes may be turning upward. The past two quarters have shown an increase in revenue year-over-year. Oil prices are rising, and the energy industry is climbing off the mat. It's scary, but buy.


It's sad to see an icon fall, but JC Penney has. The stock, which topped $80 a decade ago, now trades for $3.09. After five years of losses, Penney managed a small profit in fiscal 2017, but the red ink has flowed again in the past three quarters. Avoid.

Track Record: This is the sixth column I've written about top gainers and losers at year's end. The average 12-month gain on my recommendations has been 58.9 percent. There is one word for that kind of return: lucky.

Buying the previous year's worst losers would have given you a 41.9 percent return. If you had bought the previous year's winners you would have reaped a 21.9 percent gain. For comparison, the Standard & Poor's 500 Index averaged 16 percent for the same six periods of about 12 months each.

My two buy recommendations from last year, First Solar Inc. (FSLR) and Alnylam Pharmaceuticals Inc. (ALNY) rose 100 percent and 197 percent respectively through Dec. 15.

Bear in mind that my column recommendations are theoretical and don't reflect actual trades, trading costs or taxes. Results shouldn't be confused with the performance of portfolios I manage for clients. And past performance doesn't predict future results.

Disclosure: I own First Solar for one of my clients. With that exception, I have no positions in the stocks discussed in today's column, personally or for clients.

John Dorfman is chairman of Dorfman Value Investments LLC in Newton Upper Falls, Massachusetts, and a syndicated columnist. His firm or clients may own or trade securities discussed in this column. He can be reached at

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

click me